JPM: CureVac's new pharma partner Bayer says its COVID-19 vaccine not just an also-ran

German biotech CureVac shouldn’t be discounted from being a major COVID-19 vaccine player despite being at the tail end of the race to market.

This is according to Marianne De Backer, Bayer’s head of business development who would have helped pen its vaccine deal with CureVac, speaking at the annual J.P. Morgan healthcare conference today.